In September 2008, the group announced that its wholly-owned subsidiary, Shenzhen Liancheng Medicine Company Limited, entered into an agreement which disposed of its 70% interest in Cangnan County Hongtai Medicine Co., Ltd.
The disposal is in line with the group’s strategy of focusing on the development of high-margin exclusive and private label products.